Performance evaluation of the Vitros anti-hepatitis C virus antibody assay for use in clinical laboratories

Yongjung Park, Yoonmi Seok, Jonghyeon Choi, Hyonsuk Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: We evaluated the performance of Vitros anti-HCV assay. Design and methods: Precision performance was assessed for 20. days. A total of 1011 sera were tested for anti-HCV with Vitros and Elecsys assays. Specimens positive for any of the two assays were retested with Architect assay. Discrepant results were evaluated with recombinant immunoblot assay (RIBA) and HCV RNA quantification. Results: Total imprecision of Vitros assay was 11.6% and 3.3% CV for negative and positive QC. Among the 1011 sera, 17 showed discrepant results between the three assays. Six were positive and three negative for RIBA. HCV RNA was not detected from all discrepant cases. Sensitivity and specificity were 99.5% and 99.5% for the Vitros, and 100.0% and 99.9% for the Elecsys assay. Conclusions: Sensitivities and specificities of the anti-HCV assays were sufficiently high for use in clinical laboratories, but retesting of weak positive results may be necessary.

Original languageEnglish
Pages (from-to)175-177
Number of pages3
JournalClinical Biochemistry
Volume45
Issue number1-2
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Clinical laboratories
Hepatitis C Antibodies
Assays
RNA
Sensitivity and Specificity
Serum

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

Park, Yongjung ; Seok, Yoonmi ; Choi, Jonghyeon ; Kim, Hyonsuk. / Performance evaluation of the Vitros anti-hepatitis C virus antibody assay for use in clinical laboratories. In: Clinical Biochemistry. 2012 ; Vol. 45, No. 1-2. pp. 175-177.
@article{616d2207697940918310f75090727584,
title = "Performance evaluation of the Vitros anti-hepatitis C virus antibody assay for use in clinical laboratories",
abstract = "Objectives: We evaluated the performance of Vitros anti-HCV assay. Design and methods: Precision performance was assessed for 20. days. A total of 1011 sera were tested for anti-HCV with Vitros and Elecsys assays. Specimens positive for any of the two assays were retested with Architect assay. Discrepant results were evaluated with recombinant immunoblot assay (RIBA) and HCV RNA quantification. Results: Total imprecision of Vitros assay was 11.6{\%} and 3.3{\%} CV for negative and positive QC. Among the 1011 sera, 17 showed discrepant results between the three assays. Six were positive and three negative for RIBA. HCV RNA was not detected from all discrepant cases. Sensitivity and specificity were 99.5{\%} and 99.5{\%} for the Vitros, and 100.0{\%} and 99.9{\%} for the Elecsys assay. Conclusions: Sensitivities and specificities of the anti-HCV assays were sufficiently high for use in clinical laboratories, but retesting of weak positive results may be necessary.",
author = "Yongjung Park and Yoonmi Seok and Jonghyeon Choi and Hyonsuk Kim",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.clinbiochem.2011.10.020",
language = "English",
volume = "45",
pages = "175--177",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "1-2",

}

Performance evaluation of the Vitros anti-hepatitis C virus antibody assay for use in clinical laboratories. / Park, Yongjung; Seok, Yoonmi; Choi, Jonghyeon; Kim, Hyonsuk.

In: Clinical Biochemistry, Vol. 45, No. 1-2, 01.01.2012, p. 175-177.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Performance evaluation of the Vitros anti-hepatitis C virus antibody assay for use in clinical laboratories

AU - Park, Yongjung

AU - Seok, Yoonmi

AU - Choi, Jonghyeon

AU - Kim, Hyonsuk

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Objectives: We evaluated the performance of Vitros anti-HCV assay. Design and methods: Precision performance was assessed for 20. days. A total of 1011 sera were tested for anti-HCV with Vitros and Elecsys assays. Specimens positive for any of the two assays were retested with Architect assay. Discrepant results were evaluated with recombinant immunoblot assay (RIBA) and HCV RNA quantification. Results: Total imprecision of Vitros assay was 11.6% and 3.3% CV for negative and positive QC. Among the 1011 sera, 17 showed discrepant results between the three assays. Six were positive and three negative for RIBA. HCV RNA was not detected from all discrepant cases. Sensitivity and specificity were 99.5% and 99.5% for the Vitros, and 100.0% and 99.9% for the Elecsys assay. Conclusions: Sensitivities and specificities of the anti-HCV assays were sufficiently high for use in clinical laboratories, but retesting of weak positive results may be necessary.

AB - Objectives: We evaluated the performance of Vitros anti-HCV assay. Design and methods: Precision performance was assessed for 20. days. A total of 1011 sera were tested for anti-HCV with Vitros and Elecsys assays. Specimens positive for any of the two assays were retested with Architect assay. Discrepant results were evaluated with recombinant immunoblot assay (RIBA) and HCV RNA quantification. Results: Total imprecision of Vitros assay was 11.6% and 3.3% CV for negative and positive QC. Among the 1011 sera, 17 showed discrepant results between the three assays. Six were positive and three negative for RIBA. HCV RNA was not detected from all discrepant cases. Sensitivity and specificity were 99.5% and 99.5% for the Vitros, and 100.0% and 99.9% for the Elecsys assay. Conclusions: Sensitivities and specificities of the anti-HCV assays were sufficiently high for use in clinical laboratories, but retesting of weak positive results may be necessary.

UR - http://www.scopus.com/inward/record.url?scp=84855338168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855338168&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2011.10.020

DO - 10.1016/j.clinbiochem.2011.10.020

M3 - Article

VL - 45

SP - 175

EP - 177

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 1-2

ER -